Niagen Bioscience, Inc SEC Filings

Niagen Bioscience, Inc. (NAGE) reported insider share purchases by its Chief Financial Officer on a Form 4. On 11/14/2025, the CFO bought 4,464.962 shares of common stock in a direct transaction at a weighted average price of $6.81, with individual trade prices ranging from $6.7975 to $6.82. After this transaction, the CFO directly owned 7,372.159 shares of Niagen Bioscience common stock. On the same date, the CFO’s spouse acquired 2,220.443 shares at $6.85, which are reported as indirectly owned, bringing the indirect beneficial ownership to 2,220.443 shares.

Niagen Bioscience (NAGE) approved a share repurchase program authorizing up to $10.0 million of common stock. Purchases may occur in open market or privately negotiated transactions, or under a trading plan adopted in the future, in accordance with applicable securities laws.

The authorization expires on October 31, 2027 and can be modified, suspended, or terminated at any time at the Board’s discretion. The program does not obligate the company to buy any specific amount of shares.

Niagen Bioscience, Inc. furnished an 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025, and posted a corporate presentation on its website.

The press release is included as Exhibit 99.1 and the presentation as Exhibit 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed “filed” under the Exchange Act.

Niagen Bioscience (NAGE) reported strong Q3 2025 results. Net sales were $33,986 thousand, up from $25,580 thousand a year ago. Operating income rose to $4,236 thousand and net income reached $4,578 thousand, or $0.05 diluted earnings per share. Cash and cash equivalents were $64,290 thousand as of September 30, 2025.

For the nine months, net sales were $95,584 thousand with net income of $13,250 thousand. Operating cash flow was $12,825 thousand, reflecting improved profitability and working capital. Segment mix in Q3 showed Consumer Products at $26,017 thousand and Ingredients at $7,197 thousand. As of November 3, 2025, there were 79,806,139 common shares issued and outstanding.

The company received $2,650,000 from the Elysium California settlement. In a separate Delaware matter, a final judgment awarded $9.2 million in fees and costs plus interest; the company has appealed and disclosed a reasonably possible loss of approximately $10.4 million. Trade receivables totaled $8,506 thousand, with 64.9% concentrated among three customers, and major-customer sales in the quarter included Life Extension at 11.9% and A.S. Watson Group at 10.8%.

Niagen Bioscience, Inc. disclosed in a Current Report on Form 8-K that on October 6, 2025 it issued a press release announcing an increase to its financial outlook for the full year ending December 31, 2025. The company states the press release is furnished as Exhibit 99.1 and clarifies this information is being furnished, not filed, under the Exchange Act so it is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated. No specific revenue, earnings, or guidance figures are included in the filing text provided.

Niagen Bioscience is registering an additional 4,750,000 shares of its common stock (par value $0.001) for issuance under the 2017 Equity Incentive Plan following a stockholder-approved increase to the plan's share reserve on June 24, 2025. The filing incorporates prior S-8 registrations and references the company's recent annual and quarterly SEC reports for the disclosures that govern these awards. These shares will be available for issuance as employee and director equity awards under the amended plan.

Niagen Bioscience, Inc. has filed a Form S-8 to register 650,000 shares of its common stock for issuance under its Employee Stock Purchase Plan, enabling eligible employees and subsidiaries to acquire company shares through that plan. The Registration Statement incorporates the company’s recent annual, quarterly and current reports and refers to its previously filed description of common stock so investors can find detailed financial and disclosure history by reference.

The filing describes standard Delaware-law indemnification protections for directors and officers, the company’s authority to purchase insurance for such persons, and confirms key corporate governance documents and the ESPP are attached as exhibits. The statement is procedural and does not present standalone financial results or new material transactions that change the company’s financial condition.